

DEVELOPMENT PROGRAM FOR SMALL MOLECULES

DISCOVERY

PRECLINICAL

CLINICAL PHASE I

PHASE II


PHASE III

Approval



DISCOVERY: We conduct *in vitro* and *in vivo* studies for lead optimization to screen your chosen compounds for toxicology, safety pharmacology, metabolites, and other safety assessments to meet regulatory and scientific milestones. In addition, our Bioanalysis & Research Services provide additional support throughout development.

COLOR KEY: ● Nonclinical ● Clinical ● Currently Not Available at Altasciences



This chart is not to scale and reflects one example of a development path and sequence followed; actual sequence, length and types of studies may vary based on indication, molecule and program needs. All development programs need to be customized depending on the molecule, mechanism of action and indication. However, for biologics the studies required for each program differs to an even greater extent due to the need for relevant models and the ADME for biologics being so different than small molecules. Please [Contact us](#) to learn more about the different requirements.

DEVELOPMENT PROGRAM FOR BIOLOGICS

DISCOVERY

PRECLINICAL

CLINICAL PHASE I

PHASE II


PHASE III

Approval



DISCOVERY: We conduct *in vitro* studies for primary and secondary pharmacodynamics as well as cytokine and other assays to meet regulatory and scientific milestones. Our *in vivo* immunogenicity studies and Bioanalysis & Research Services provide additional support throughout.

COLOR KEY: ● Nonclinical ● Clinical ● Currently Not Available at Altasciences



This chart is not to scale and reflects one example of a development path and sequence followed; actual sequence, length and types of studies may vary based on indication, molecule and program needs. All development programs need to be customized depending on the molecule, mechanism of action and indication. However, for biologics the studies required for each program differs to an even greater extent due to the need for relevant models and the ADME for biologics being so different than small molecules. Please [Contact us](#) to learn more about the different requirements.

DEVELOPMENT PROGRAM FOR SMALL MOLECULES

DISCOVERY

PRECLINICAL

CLINICAL PHASE I


PHASE II

PHASE III

Approval



PRECLINICAL: Our Preclinical Services include pharmacodynamics, DRF/MTD, and subacute repeated dose toxicity studies in rodent and non-rodent species to move your program toward clinical trials and then as it progresses towards regulatory submission.



This chart is not to scale and reflects one example of a development path and sequence followed; actual sequence, length and types of studies may vary based on indication, molecule and program needs. All development programs need to be customized depending on the molecule, mechanism of action and indication. However, for biologics the studies required for each program differs to an even greater extent due to the need for relevant models and the ADME for biologics being so different than small molecules. Please [Contact us](#) to learn more about the different requirements.

DEVELOPMENT PROGRAM FOR BIOLOGICS

DISCOVERY

PRECLINICAL

CLINICAL PHASE I

PHASE II


PHASE III

Approval



PRECLINICAL: Our Preclinical Services include *in vivo* pharmacodynamics, animal ADME, DRF/MTD, and subacute repeated dose toxicity studies in rodent and non-rodent species to move your program toward clinical trials.

COLOR KEY: ● Nonclinical ● Clinical ● Currently Not Available at Altasciences



This chart is not to scale and reflects one example of a development path and sequence followed; actual sequence, length and types of studies may vary based on indication, molecule and program needs. All development programs need to be customized depending on the molecule, mechanism of action and indication. However, for biologics the studies required for each program differs to an even greater extent due to the need for relevant models and the ADME for biologics being so different than small molecules. Please [Contact us](#) to learn more about the different requirements.

DEVELOPMENT PROGRAM FOR SMALL MOLECULES

DISCOVERY

PRECLINICAL

CLINICAL PHASE I

PHASE II


PHASE III

Approval



PHASE I: Altasciences is a recognized leader in conducting first-in-human, proof of concept, and related studies in both healthy normal volunteers and patient populations. We also conduct nonclinical subchronic repeated dose toxicity studies in rodent and non-rodent species that complement early phase clinical drug development.

COLOR KEY: ● Nonclinical ● Clinical ● Currently Not Available at Altasciences



This chart is not to scale and reflects one example of a development path and sequence followed; actual sequence, length and types of studies may vary based on indication, molecule and program needs. All development programs need to be customized depending on the molecule, mechanism of action and indication. However, for biologics the studies required for each program differs to an even greater extent due to the need for relevant models and the ADME for biologics being so different than small molecules. Please [Contact us](#) to learn more about the different requirements.

DEVELOPMENT PROGRAM FOR BIOLOGICS

DISCOVERY

PRECLINICAL

CLINICAL PHASE I

PHASE II


PHASE III

Approval



PHASE I: Altasciences is a recognized leader in conducting first-in-human, proof of concept, and related studies in both healthy normal volunteers and patient populations. We also conduct nonclinical subchronic repeated dose toxicity studies in rodent and non-rodent species that complement early phase clinical drug development.

COLOR KEY: ● Nonclinical ● Clinical ● Currently Not Available at Altasciences



This chart is not to scale and reflects one example of a development path and sequence followed; actual sequence, length and types of studies may vary based on indication, molecule and program needs. All development programs need to be customized depending on the molecule, mechanism of action and indication. However, for biologics the studies required for each program differs to an even greater extent due to the need for relevant models and the ADME for biologics being so different than small molecules. Please [Contact us](#) to learn more about the different requirements.

DEVELOPMENT PROGRAM FOR SMALL MOLECULES

DISCOVERY


PRECLINICAL

CLINICAL PHASE I

PHASE II


PHASE III

Approval



PHASE II: Our Clinical Services include all the clinical pharmacology studies to provide the data to advance you compound through Phase II. We also conduct nonclinical chronic repeated dose toxicity studies in rodent and non-rodent species, to complement your clinical drug development.

COLOR KEY: ● Nonclinical ● Clinical ● Currently Not Available at Altasciences



This chart is not to scale and reflects one example of a development path and sequence followed; actual sequence, length and types of studies may vary based on indication, molecule and program needs. All development programs need to be customized depending on the molecule, mechanism of action and indication. However, for biologics the studies required for each program differs to an even greater extent due to the need for relevant models and the ADME for biologics being so different than small molecules. Please [Contact us](#) to learn more about the different requirements.

DEVELOPMENT PROGRAM FOR BIOLOGICS

DISCOVERY


PRECLINICAL

CLINICAL PHASE I

PHASE II


PHASE III

Approval



PHASE II: Our Clinical Services include all the clinical pharmacology studies to provide the data to advance you compound through Phase II. We also conduct nonclinical chronic repeated dose toxicity studies in rodent and non-rodent species to complement your clinical drug development.

COLOR KEY: ● Nonclinical ● Clinical ● Currently Not Available at Altasciences



This chart is not to scale and reflects one example of a development path and sequence followed; actual sequence, length and types of studies may vary based on indication, molecule and program needs. All development programs need to be customized depending on the molecule, mechanism of action and indication. However, for biologics the studies required for each program differs to an even greater extent due to the need for relevant models and the ADME for biologics being so different than small molecules. Please [Contact us](#) to learn more about the different requirements.

DEVELOPMENT PROGRAM FOR SMALL MOLECULES

DISCOVERY

PRECLINICAL

CLINICAL PHASE I

PHASE II


PHASE III

Approval



PHASE III: As your test article undergoes Phase III efficacy studies elsewhere, we support its development through clinical studies ranging from drug-drug interaction, renal or hepatic impaired, QT assessments, and, as needed, drug-alcohol interaction, human abuse potential, and driving simulation. We also conduct a range of critical nonclinical studies in rodent and non-rodent species including reproductive toxicology.

COLOR KEY: ● Nonclinical ● Clinical ● Currently Not Available at Altasciences



This chart is not to scale and reflects one example of a development path and sequence followed; actual sequence, length and types of studies may vary based on indication, molecule and program needs. All development programs need to be customized depending on the molecule, mechanism of action and indication. However, for biologics the studies required for each program differs to an even greater extent due to the need for relevant models and the ADME for biologics being so different than small molecules. Please [Contact us](#) to learn more about the different requirements.

DEVELOPMENT PROGRAM FOR BIOLOGICS

DISCOVERY


PRECLINICAL

CLINICAL PHASE I

PHASE II


PHASE III

Approval



PHASE III: As your biologic undergoes Phase III efficacies studies elsewhere, we support its development through clinical studies. We also conduct a range of critical nonclinical studies in rodent and non-rodent species including reproductive toxicology.

COLOR KEY: ● Nonclinical ● Clinical ● Currently Not Available at Altasciences



This chart is not to scale and reflects one example of a development path and sequence followed; actual sequence, length and types of studies may vary based on indication, molecule and program needs. All development programs need to be customized depending on the molecule, mechanism of action and indication. However, for biologics the studies required for each program differs to an even greater extent due to the need for relevant models and the ADME for biologics being so different than small molecules. Please [Contact us](#) to learn more about the different requirements.